```json
{
"content": [
{
"type": "paragraph",
"content": "GABA Supplements are organic compounds derived from gamma-aminobutyric acid, a neurotransmitter used to manage stress, anxiety, and sleep disorders. The GABA Supplements market size is projected to witness robust growth outlook through 2033, driven by rising mental health awareness and the surge in demand for natural wellness solutions. This market forecast underscores the industry expansion potential, particularly in regions prioritizing preventive healthcare and nutraceutical innovation. The report analyzes global demand, technological advancements, and regulatory frameworks shaping this niche sector."
},
{
"type": "chart",
"chartType": "segment-stacked",
"data": {
"segments": ["Capsules", "Powder", "Chewables"],
"periods": ["2021", "2022", "2023", "2024", "2025", "2026", "2027", "2028", "2029", "2030", "2031", "2032", "2033"],
"values": [
[120, 130, 145, 160, 175, 190, 205, 220, 235, 250, 265, 280, 295], // Capsules
[80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140], // Powder
[50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110] // Chewables
]
}
},
{
"type": "paragraph",
"content": "The global GABA Supplements market is anticipated to expand at a compound annual growth rate (CAGR) of ~7.2% from 2026 to 2033, reaching an estimated USD 2.4 billion by the end of the forecast period. Key drivers include advancements in bioavailability enhancement technologies, regulatory approvals for functional food applications, and a shift toward plant-based formulations. North America leads the market, fueled by high healthcare spending, while Asia-Pacific emerges as the fastest-growing region due to urbanization and rising disposable incomes. Competitive dynamics are intensifying as manufacturers invest in R&D to differentiate offerings in a saturated landscape."
}
]
}
```
